Alendronate - Risk for esophageal stricture

Journal of the American Geriatrics Society

Volumn 46, Issue 12, 1998, Pages 1581-1582

  Yue, Qun Ying ^a   Mortimer, Orjan ^a  

^a MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; BONE DENSITY; CLINICAL ARTICLE; DRUG EFFECT; ESOPHAGITIS; ESOPHAGUS INJURY; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; FEMALE; HUMAN; LETTER; POSTMENOPAUSE OSTEOPOROSIS;

EID: 0031770899     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1998.tb01550.x     Document Type: Letter

References (5)

1. Castell DO,. Pill esophagitis-The case of alendronate. N Engl J Med 1996;335:1058-1059.
2. Maconi G., Porro GB,. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995;90:1889-1890.
3. Liberman UA, Weiss SR, Bröil J., et al,. Effect of oral alendronate on bone mineral density and the incidence of fractures on postmenopausal osteoporosis. N Engl J Med 1995;333:1437-1443.
4. Devogelaer JP, Broil H., Correa-Rotter R., et al,. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osterporosis. Bone 1996;18:141-150.
5. Mackay E., Wilton LV, Pearce G., et al,. Alendronate and oesophageal reactions. Pharmacoepidemiol Drug Safety 1997;6(suppl 2):S20-S20.